MBX Biosciences, Inc. announced the departure of CEO Kent P. Hawryluk effective July 13, 2026, and the appointment of Steven Hoerter as new President and CEO, effective the same date. John Smither was also appointed as Chief Financial Officer effective July 13, 2026. MBX Biosciences, Inc. is a biotechnology company focused on developing therapeutic solutions for rare diseases.
